Study of Blood Multi-Gene Methylation Changes to Monitor Treatment Response in Adults With Esophageal Cancer

What this Trial Is About

Researchers are investigating how changes in multigene methylation levels in the blood relate to treatment responses in people with esophageal cancer. The study aims to understand if these methylation changes correspond with objective response rates seen in imaging scans and serum tumor markers. Secondary goals include examining how methylation patterns relate to progression-free survival, comparing methylation to standard biomarkers, and exploring if methylation can guide treatment adjustments. Participants are grouped based on their treatment approach surgery alone, surgery after neoadjuvant therapy, active surveillance after neoadjuvant therapy, or definitive chemoradiotherapy with or without immunotherapy. All participants undergo regular blood tests for multigene methylation during follow-up, with specific timing depending on their treatment group. The study involves multiple assessments through pre-scheduled timepoints extending up to five years post-treatment. Throughout the study, participants will have blood samples taken at various intervals up to five years to measure methylation levels. Additional evaluations include tumor marker tests, imaging scans such as contrast-enhanced CT, PETCT, ultrasound, X-rays, MRI, and endoscopies following a set schedule based on the treatment group. Researchers will monitor these results to evaluate treatment response and disease progression over time, ensuring comprehensive long-term follow-up and safety monitoring.

Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma